Clinical Trial Update: Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lenalidomide versus placebo in patients with low-risk myelodysplastic syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Fundación General de la Universidad de Salamanca | Conditions: Myelodysplastic Syndrome | Phase 3 | Status: COMPLETED